Jul. 30 at 12:08 PM
H.C. Wainwright⬆️
$AXGN's PT to
$53 (was
$50) plus increased its revenue projections and reiterated its Buy rating.
$IART $SYK MDT AMIX
Citizens⬆️AxoGen's PT to
$55 and said -- We reiterate our Market Outperform rating and raise our price target to
$55 from
$50 on shares of AxoGen following the release of 2Q26 results.
Following a stellar 1Q, with sales +26.6% y/y, there was some concern about the potential for a sizable drop-off in 2Q and 2H26 growth performance, which we think was largely abated yesterday morning.
Frankly, no other company that we cover in the MedTech realm is delivering results like AXGN currently is, and we further highlight the scarce competition (no other BLAs here), and the vastly underserved population of peripheral nerve repairs that remain targets ahead.
